---
schema_version: "secwatch.filing_event.v1"
accession: "0001398733-26-000035"
form_type: "8-K"
ticker: "AQST"
cik: "0001398733"
company_name: "Aquestive Therapeutics, Inc."
filed_at: "2026-08-10T11:05:44+00:00"
generated_at: "2026-08-10T11:10:09.512010+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Aquestive reports positive Anaphylm human factors and PK study results; NDA resubmission on track for Q3 2026

## Summary
- Median pouch-open time cut from 17s to 3s; incorrect film placement down >80% in revised HF study.
- PK study: self-admin Cmax 391.7 pg/mL vs clinician 357.6 and IM 334.5; Tmax 12 min vs 45 min for IM.
- Top-of-tongue placement still gave Cmax >100 pg/mL and PD comparable to injectable epinephrine.
- No serious adverse events or discontinuations in PK study; no administration errors in self-administration arm.
- NDA resubmission on track for Q3 2026; also advancing filings in Canada, UK, EU.

## SEC filing metadata
- accession: 0001398733-26-000035
- form_type: 8-K
- ticker: AQST
- cik: 0001398733
- company_name: Aquestive Therapeutics, Inc.
- filed_at: 2026-08-10T11:05:44+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1398733/000139873326000035/0001398733-26-000035-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1398733/000139873326000035/aqst-20260810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001398733-26-000035
- JSON: https://secwatch.observer/filing/0001398733-26-000035.json
- Plain text: https://secwatch.observer/filing/0001398733-26-000035.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.